Title: Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin.
Journal: Toxicology in vitro : an international journal published in association with BIBRA 20180201
Title: Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.
Journal: Chemico-biological interactions 20160425
Title: Antioncogenic and Oncogenic Properties of Nrf2 in Arsenic-induced Carcinogenesis.
Journal: The Journal of biological chemistry 20151106
Title: Nrf2/p62 signaling in apoptosis resistance and its role in cadmium-induced carcinogenesis.
Journal: The Journal of biological chemistry 20141010
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Journal: Biochemical pharmacology 20130401
Title: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Journal: Nature medicine 20130201
Title: Bax and Bcl-xL exert their regulation on different sites of the ceramide channel.
Journal: The Biochemical journal 20120701
Title: Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
Journal: Cell death & disease 20120701
Title: In vivo imaging of drug-induced mitochondrial outer membrane permeabilization at single-cell resolution.
Journal: Cancer research 20120615
Title: Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Journal: Blood 20120614
Title: Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120601
Title: Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.
Journal: Molecular cancer therapeutics 20120401
Title: ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
Journal: Cancer chemotherapy and pharmacology 20120301
Title: WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Journal: Laboratory investigation; a journal of technical methods and pathology 20120301
Title: 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120301
Title: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210
Title: Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210
Title: From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210
Title: A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
Journal: PloS one 20120101
Title: Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens.
Journal: The Journal of pharmacology and experimental therapeutics 20111201
Title: The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
Journal: Molecular cancer therapeutics 20111201
Title: Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.
Journal: Biochemical pharmacology 20111101
Title: Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis.
Journal: Cell death & disease 20111101
Title: Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
Journal: Pathology 20111001
Title: Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.
Journal: Blood 20110811
Title: Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Journal: Experimental hematology 20110801
Title: Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Journal: Cancer research 20110701
Title: BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.
Journal: Blood 20110630
Title: Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110615
Title: The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.
Journal: Biochemical and biophysical research communications 20110506
Title: Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
Journal: Journal of medicinal chemistry 20110324
Title: Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110315
Title: ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis.
Journal: Oncology reports 20110301
Title: Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110301
Title: Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells.
Journal: PloS one 20110101
Title: Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
Journal: PloS one 20110101
Title: Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Journal: The Lancet. Oncology 20101201
Title: A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax).
Journal: Molecular cancer therapeutics 20101101
Title: Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737.
Journal: Cancer biology & therapy 20101101
Title: Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Journal: Journal of medicinal chemistry 20101014
Title: The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
Journal: Cancer chemotherapy and pharmacology 20101001
Title: Drugs targeting Bcl-2 family members as an emerging strategy in cancer.
Journal: Expert reviews in molecular medicine 20100908
Title: Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100815
Title: Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.
Journal: Molecular cancer therapeutics 20100301
Title: Aileron staples peptides.
Journal: Chemistry & biology 20090925
Title: Update on developmental therapeutics for acute lymphoblastic leukemia.
Journal: Current hematologic malignancy reports 20090701
Title: Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.
Journal: Cell death and differentiation 20090301
Title: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090215
Title: Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
Journal: Journal of cellular physiology 20090101
Title: Mimicking the BH3 domain to kill cancer cells.
Journal: Oncogene 20081201
Title: Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Journal: Journal of medicinal chemistry 20081113
Title: ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.
Journal: Molecular cancer therapeutics 20081001
Title: Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
Journal: Pediatric blood & cancer 20080601
Title: Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080601
Title: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Journal: Cancer research 20080501
Title: A matter of life and death.
Journal: Cancer cell 20020201
Title: An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
Journal: Cancer research 20001101
Title: Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1181-1189.
Title: Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11(4):1026-1035.
Title: Chen J, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9.